Telix Pharmaceuticals Limited (ASX:TLX)
Australia · Delayed Price · Currency is AUD 14.72
-0.13 (-0.88%)
May 15, 2026, 4:10 PM AEST
Telix Pharmaceuticals Employees
As of December 31, 2025, Telix Pharmaceuticals had 1,184 total employees, including 1,120 full-time and 64 part-time employees. The number of employees increased by 950 or 405.98% compared to the previous year.
Employees
1,184
Change
950
Growth
405.98%
Revenue / Employee
1.05M AUD
Profits / Employee
-9.27K AUD
Market Cap
4.99B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 1,184 | - | - | 1,120 | 64 |
| Mar 31, 2024 | 431 | 197 | 84.19% | 415 | 16 |
| Dec 31, 2022 | 234 | 76 | 48.10% | 234 | 0 |
| Dec 31, 2021 | 158 | - | - | 158 | 0 |
| Dec 31, 2017 | 9 | - | - | 9 | 0 |
Related Stocks
| Company Name | Employees |
|---|---|
| CSL Limited | 29,904 |
| Clarity Pharmaceuticals | 88 |
| Mesoblast | 81 |
| Starpharma Holdings | 40 |
| Opthea | 33 |
Telix Pharmaceuticals News
- 1 day ago - Telix Announces Collaborations to Explore PSMA-PET Imaging in Emerging Prostate Cancer Treatment Approaches - GlobeNewsWire
- 12 days ago - New Publication Demonstrates TLX250-Px (Zircaix®) Potential in Diagnosing Kidney Cancers Beyond ccRCC - GlobeNewsWire
- 16 days ago - Telix Presents Phase 2 OPTIMAL-PSMA Dosimetry Data For TLX597-Tx In Prostate Cancer Treatment - Nasdaq
- 16 days ago - TLX101-Px (Pixlumi®) MAA Accepted in Europe - GlobeNewsWire
- 17 days ago - Telix Pharmaceuticals Transcript: Status update - Transcripts
- 17 days ago - OPTIMAL-PSMA Trial of TLX597-Tx Next Generation RLT Presented at IPCS 2026 Highlighting Therapeutic Potential in Prostate Cancer - GlobeNewsWire
- 19 days ago - Educational Webinar: Unlocking the Potential of PSMA Therapy, A Next‑Generation Portfolio Approach - GlobeNewsWire
- 25 days ago - ProstACT Global Phase 3 (Part 1) Selected as Late-Breaking Abstract at ASCO 2026 - GlobeNewsWire